PMC7592682_01
Timeline of disease course of case 1. A. Therapeutic details according to days from illness onset and days from hospital admission. B. Chest CT images of the patient at 4 stages. Chest CT scans were performed on hospital day 1 (I), day 8 (II), day 13 (III), and day 26 (IV), respectively. Areas within green lines indicate the lesions of lungs analyzed by AI system. C. The changes of mass of lesions at 4 stages and the adjusted dosage of MP (mg/per day) depending on CT scans. Mass was calculated as: M = V * (A + 1000)/1000 , where M is mass in g, V is volume in cm3, and A is mean attenuation in Hounsfield Unit (HU, reflects the degree of X-ray absorption of the tissue). MP, Methylprednisolone.
xst-28-xst200710-g001.jpg
PMC7592682_01_xst-28-xst200710-g001.jpg
xst-28-xst200710-g001
Chest CT scan on hospital day 1showed multifocal ground glass opacities (GGO) and infiltrates located on bilateral lungs (Fig. 1). At day 2, because of progressive dyspnea, immune globulin and low-dose Methylprednisolone (MP) at 40 mg qd (0.67 mg/kg/d) for 6 days were added (Fig. 1A), and the patient's clinical condition seemed under control. A follow-up CT scan confirmed the deterioration of pneumonia with remarkably enlarged diffused bilateral opacities (Fig. 1B-II), and the mass of lesion presented a sharp increase (Fig. 1C). The CT scan on day 13 and day 26 showed bilateral diffuse opacities and infiltrates dissipated gradually (Fig. 1B-III and IV; 1C).
PMC7592682_02
Timeline of disease course of case 2. A. Therapeutic details according to days from illness onset and days from hospital admission. B. Chest CT images of the patient at 4 stages. Chest CT scans were performed on hospital day 2 (I), hospital day 9 (II), day 14 (III), and day 36 (IV), respectively. Areas within green lines indicate the lesions of lungs analyzed by AI system. C. The changes of mass of lesions at 4 stages and the adjusted dosage of MP (mg/per day) depending on CT scans. Mass was calculated as: M = V * (A + 1000)/1000 , where M is mass in g, V is volume in cm3, and A is mean attenuation in Hounsfield Unit (HU, reflects the degree of X-ray absorption of the tissue). MP, Methylprednisolone.
xst-28-xst200710-g002.jpg
PMC7592682_02_xst-28-xst200710-g002.jpg
xst-28-xst200710-g002
The chest CT scan on hospital day 2 showed bilateral ground glass opacities (Fig. 2B-I). Although the patient was accommodated with oxygenation support, arbidol, immunoglobulin, and MP 40 mg/day (0.62 mg/kg/d) (Fig. 2A) on admission, his weakness and dyspnea persisted. On hospital day 9, his body temperature rose to 38.2 C, follow-up CT showed obvious peripheral infiltration on the right lung (Fig. 2B-II), and the mass of lesion increased (Fig. 2C). At hospital day 14, CT image showed previous infiltration partially dissipated with small patchy consolidation (Fig. 2B-III), and the mass of involvement were also reduced markedly (Fig. 2C). At day 36, CT images showed previous infiltration significantly dissipated and the consolidation was partially absorbed (Fig. 2B-IV), and the patient was discharged on day 40.
PMC7592682_03
Timeline of disease course of case 3. A. Therapeutic details according to days from illness onset and days from hospital admission. B. Chest CT images of the patient at 4 stages. Chest CT scans were performed on day of admission (I), hospital day 7 (II), day 14 (III), and day 25 (IV), respectively. Areas within green lines indicate the lesions of lungs analyzed by AI system. C. The changes of mass of lesions at 4 stages and the adjusted dosage of MP (mg/per day) depending on CT scans. Mass was calculated as: M = V * (A + 1000)/1000 , where M is mass in g, V is volume in cm3, and A is mean attenuation in Hounsfield Unit (HU, reflects the degree of X-ray absorption of the tissue). MP, Methylprednisolone.
xst-28-xst200710-g003.jpg
PMC7592682_03_xst-28-xst200710-g003.jpg
xst-28-xst200710-g003
The pre-admission chest CT scan showed multifocal GGO and infiltrates on bilateral lungs (Fig. 3B-I). On hospital day 7, a follow-up CT scan revealed enlarged diffused bilateral opacities and sharp increased lesion mass of COVID involvement (Fig. 3C). Although the CT scans on day 14 showed only slightly-dissipated bilateral diffuse opacities and infiltrates, and the mass of lesion increased (Fig. 3B-III, IV, 3C), the mass of lesions was reduced markedly (Fig. 3C).